Zacks Research Issues Pessimistic Outlook for AGIO Earnings

Key Points

• Zacks Research has downgraded its earnings estimates for Agios Pharmaceuticals, projecting a FY2025 EPS of ($7.52), which is slightly worse than the previous estimate of ($7.50).
• The company reported Q2 earnings of ($1.93) per share, missing the consensus estimate by ($0.19), while generating revenue of $12.50 million, surpassing the expected $9.46 million.
• Despite the negative outlook, Agios Pharmaceuticals has received a "Moderate Buy" rating from analysts, with an average target price of $56.00 for the stock.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities research analysts at Zacks Research dropped their FY2025 EPS estimates for shares of Agios Pharmaceuticals in a note issued to investors on Tuesday, October 7th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of ($7.52) per share for the year, down from their previous estimate of ($7.50). Zacks Research currently has a "Strong Sell" rating on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals' Q4 2025 earnings at ($2.09) EPS, Q2 2026 earnings at ($1.91) EPS, Q3 2026 earnings at ($1.90) EPS, Q4 2026 earnings at ($1.90) EPS, FY2026 earnings at ($7.46) EPS, Q1 2027 earnings at ($1.59) EPS, Q2 2027 earnings at ($1.60) EPS, Q3 2027 earnings at ($1.55) EPS and FY2027 earnings at ($6.14) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%.

Other equities research analysts have also issued reports about the stock. Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Weiss Ratings reissued a "hold (c-)" rating on shares of Agios Pharmaceuticals in a report on Wednesday. Bank of America reduced their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, HC Wainwright reissued a "buy" rating and set a $56.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Trading Up 4.2%

Shares of Agios Pharmaceuticals stock opened at $42.60 on Thursday. The firm has a market capitalization of $2.48 billion, a PE ratio of 3.87 and a beta of 0.83. The firm's 50 day moving average is $37.68 and its 200 day moving average is $34.02. Agios Pharmaceuticals has a 1 year low of $23.42 and a 1 year high of $62.58.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,651 shares of the company's stock in a transaction on Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the transaction, the chief financial officer owned 33,870 shares in the company, valued at approximately $1,245,399.90. This represents a 9.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Brian Goff sold 11,085 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $36.67, for a total transaction of $406,486.95. Following the transaction, the chief executive officer owned 123,528 shares in the company, valued at approximately $4,529,771.76. The trade was a 8.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,282 shares of company stock valued at $855,825 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 320 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 499 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Agios Pharmaceuticals by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company's stock valued at $4,393,000 after purchasing an additional 512 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Agios Pharmaceuticals by 0.3% in the second quarter. Nordea Investment Management AB now owns 224,746 shares of the biopharmaceutical company's stock valued at $7,520,000 after purchasing an additional 573 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Agios Pharmaceuticals by 1.2% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 55,284 shares of the biopharmaceutical company's stock valued at $1,839,000 after purchasing an additional 633 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.